Diagnosis Value of SEMA4C in Breast Cancer
Sponsor: Hubei Cancer Hospital
Listed as NCT03662633, this observational or N/A phase trial focuses on Breast Neoplasm Female and remains ongoing. Sponsored by Hubei Cancer Hospital, it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Nov 2024 — Present [monthly]
Unknown
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Nov 2022 — Jul 2024 [monthly]
Not Yet Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Not Yet Recruiting
▶ Show 5 earlier versions
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
Oct 2018 — Nov 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hubei Cancer Hospital
- Qilu Hospital of Shandong University
- The First Affiliated Hospital with Nanjing Medical University
- The First People's Hospital of Jingzhou
- Tongji Hospital
- Wuhan Central Hospital
- Xiangyang Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.